Clinical Trials Logo

Clinical Trial Summary

According to the results of the phase II study, choose the best dose of JINTOPIN AQ for short SGA children, further to evaluate the efficacy and safety of the treatment of short SGA children.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03245333
Study type Interventional
Source GeneScience Pharmaceuticals Co., Ltd.
Contact Xiaohua Feng
Phone 0431-85170552
Email fengxiaohua@gensci-china.com
Status Recruiting
Phase Phase 3
Start date December 2014

See also
  Status Clinical Trial Phase
Completed NCT05059093 - Developing and Testing AI Models for Fetal Biometry and Amniotic Volume Assessment in Fetal Ultrasound Scans.
Recruiting NCT02375620 - Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat SGA Children With Short Stature Phase 2
Not yet recruiting NCT05043753 - "Fetal gRowth AbnorMality dEtection Trial" N/A
Not yet recruiting NCT05070234 - Genetic Diagnosis and Human Growth Hormone Treatment in Small for Gestational Age Children With Short Stature
Active, not recruiting NCT05343403 - Parental Participation on the Neonatal Ward - the neoPARTNER Study
Not yet recruiting NCT05436119 - Select Nutrient and Gene Variant Analysis in a Targeted Diet and Lifestyle Intervention Reduces Preterm Birth
Recruiting NCT04315545 - Pregnancy Outcomes and Maternal Insulin Sensitivity
Completed NCT03221933 - A Study of Recombinant Human Growth Hormone Injection(JINTOPIN AQ)for Short Children With Small for SGA Phase 2
Not yet recruiting NCT04050488 - Zinc Supplementation on Very Low Birth Weight Infant Phase 4
Recruiting NCT05144035 - A Real World Study of the Effect of Early PEG-rhGH Therapy on Cognitive Development of SGA Infants Phase 4